![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 09, 2013 7:25:40 AM
NanoViricides, Inc. is one of many companies that live within their means and set priorities to spend their money wisely. They are a frugal company. Can our government do the same?
Nanoviricides, Inc. said it had determined after several years of studying cGMP manufacturing options, that building a pilot facility for clinical drug manufacturing was the most appropriate move.
"This will be a unique, state-of-the-art cGMP facility for the pilot scale production of nanomedicines," said president and chairman of NanoViricides’ Anil R. Diwan.
"Along with his great experience, Andy Hahn brings an acute grasp of a wide range of issues that is critically important in making such a challenging endeavor a success."
Hahn, who holds a BA in Architecture from Princeton University, has almost 30 years of architecture, design, and project management experience in the creation of new and refurbished facilities from his time at the Bristol-Myers Squibb Company.
He was the senior director of engineering, pharmaceutical facilities, and global engineering at this company, and is recently retired.
His responsibility at Bristol-Myers Squibb entailed the worldwide design and construction of pharmaceutical plants, pilot plants, clinical supply facilities, and research laboratories and offices, all relevant to NanoViricides’ current project.
"Mr Hahn will assist the company in realizing its goal of a first class cGMP manufacturing plant as well as laboratory space," said NanoViricides’ CEO Eugene Seymour.
"Andy Hahn will be instrumental in helping the company achieve this goal that will enable us to expedite our various drug development programs."
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM